Postępy Dermatologii i Alergologii

Full text

5/2026 vol. 43
Original paper

The IL-23/IL-17 axis and related biomarkers drive coronary microvascular dysfunction independently of systemic hypertension in psoriasis

Peng Zhou 1
,
Xiong Song 1
,
HuaLing She 2
,
Pengzhuo Xiao 1

  1. Department of Cardiology, The First Affiliated Hospital of Yangtze University, Jingzhou, China

  2. Jingzhou Xucheng Hemodialysis Center, Jingzhou, China

Adv Dermatol Allergol 2026; XLIII (5): 559-569

DOI: https://doi.org/10.5114/ada.2026.166085
Data publikacji online: 2026/10/27
Article file
PDiA The IL-23.pdf
  1. Bao MH, Lv QL, Li HG, et al. A novel putative role of TNK1 in atherosclerotic inflammation implicating the Tyk2/STAT1 pathway. Mediators Inflamm 2020; 2020: 6268514.
  2. Brush JE Jr, Cannon RO 3rd, Schenke WH, et al. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med 1988; 319: 1302-7.
  3. Camici PG, d’Amati G, Rimoldi O. Coronary microvascular dysfunction: mechanisms and functional assessment. Nat Rev Cardiol 2015; 12: 48-62.
  4. Cortigiani L, Rigo F, Gherardi S, et al. Coronary flow reserve during dipyridamole stress echocardiography predicts mortality. JACC Cardiovasc Imaging 2012; 5: 1079-85.
  5. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009; 9: 556-67.
  6. Gan LM, Svedlund S, Wittfeldt A, et al. Incremental value of transthoracic Doppler echocardiography-assessed coronary flow reserve in patients with suspected myocardial ischemia undergoing myocardial perfusion scintigraphy. J Am Heart Assoc 2017; 6: e004875.
  7. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.
  8. Gelfand JM, Shin DB, Duffin KC et al. A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S). J Invest Dermatol 2020; 140: 1784-93.e2.
  9. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71.
  10. Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol 2018; 201: 1605-13.
  11. Hot A, Lenief V, Miossec P. Combination of IL-17 and TNFa induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells. Ann Rheum Dis 2012; 71: 768-76.
  12. Ikonomidis I, Papadavid E, Makavos G, et al. Lowering interleukin-12 activity improves myocardial and vascular function compared with tumor necrosis factor-a antagonism or cyclosporine in psoriasis. Circ Cardiovasc Imaging 2017; 10: e006283.
  13. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med 2014; 371: 326-38.
  14. Libby P, Hansson GK. Inflammation and immunity in diseases of the arterial tree: players and layers. Circ Res 2015; 116: 307-11.
  15. Liu Y, Zhu H, Su Z, et al. IL-17 contributes to cardiac fibrosis following experimental autoimmune myocarditis by a PKCb/Erk1/2/NF-kB-dependent signaling pathway. Int Immunol 2012; 24: 605-12.
  16. Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol 2014; 32: 227-55.
  17. Lynde CW, Poulin Y, Vender R, et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol 2014; 71: 141-50.
  18. Madhur MS, Lob HE, McCann LA, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 2010; 55: 500-7.
  19. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010; 31: 1000-6.
  20. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012; 11: 763-76.
  21. Murthy VL, Naya M, Foster CR, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation 2012; 126: 1858-68.
  22. Nguyen H, Chiasson VL, Chatterjee P, et al. Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension. Cardiovasc Res 2013; 97: 696-704.
  23. Norlander AE, Madhur MS, Harrison DG. The immunology of hypertension. J Exp Med 2018; 215: 21-33.
  24. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62: 263-71.
  25. Pellikka PA, Arruda-Olson A, Chaudhry FA, et al. Guidelines for performance, interpretation, and application of stress echocardiography in ischemic heart disease: from the American Society of Echocardiography. J Am Soc Echocardiogr 2020; 33: 1-41.e8.
  26. Pepine CJ, Anderson RD, Sharaf BL, et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia: results from the National Heart, Lung and Blood Institute WISE (Women’s Ischemia Syndrome Evaluation) study. J Am Coll Cardiol 2010; 55: 2825-32.
  27. Piaserico S, Osto E, Famoso G, et al. Long-term prognostic value of coronary flow reserve in psoriasis patients. Atherosclerosis 2019; 289: 57-63.
  28. Pietrowski E, Bender B, Huppert J, et al. Pro-inflammatory effects of interleukin-17A on vascular smooth muscle cells involve NAD(P)H-oxidase-derived reactive oxygen species. J Vasc Res 2011; 48: 52-8.
  29. Pu Y, Zhou Y, Guo T, et al. MIF promotes phenotypic switching of VSMCs via AKT/mTOR-mediated autophagy regulation in aortic dissection. FASEB J 2025; 39: e71079.
  30. Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet 2019; 394: 831-9.
  31. Saleh MA, Norlander AE, Madhur MS. Inhibition of interleukin-17A, but not interleukin-17F, signaling lowers blood pressure and reduces end-organ inflammation in angiotensin II-induced hypertension. JACC Basic Transl Sci 2016; 1: 606-16.
  32. Samarasekera EJ, Neilson JM, Warren RB, et al. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol 2013; 133: 2340-6.
  33. Schiattarella GG, Alcaide P, Condorelli G, et al. Immunometabolic mechanisms of heart failure with preserved ejection fraction. Nat Cardiovasc Res 2022; 1: 211-22.
  34. Schüler R, Brand A, Klebow S, et al. Antagonization of IL-17A attenuates skin inflammation and vascular dysfunction in mouse models of psoriasis. J Invest Dermatol 2019; 139: 638-47.
  35. Tang S, Zhou W, Li C, et al. CircUBE3A inhibited endothelium–mesenchymal transition by promoting UBE3A mRNA degradation via ac4C modification in diabetic vascular impairment. Biochem Pharmacol 2026; 251: 118091.
  36. Taqueti VR, Solomon SD, Shah AM, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J 2018; 39: 840-9.
  37. von Stebut E, Boehncke WH, Ghoreschi K, et al. IL-17A in psoriasis and beyond: cardiovascular and metabolic implications. Front Immunol 2020; 10: 3096.
  38. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17: 1410-22.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Indexed in
pubmed
Integrated with
integrated with publons
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications